Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.50Mangalam Drugs and Organics Ltd, operating within the Healthcare Services industry, showcases a mixed financial performance. The company demonstrates notable strength in solvency and profitability. However, liquidity, efficiency, and coverage ratios reveal potential areas of concern. While the company has experienced a decline in revenue and EPS growth, its operating profit and asset growth show promise. The company's ability to manage its debts is a notable strength, but its ability to meet its short-term obligations needs improvements. Overall, the company's financial health presents a complex picture, requiring further scrutiny to leverage its strengths and address its weaknesses.
Health Score : 4.50Mangalam Drugs and Organics Ltd, operating within the Healthcare Services industry, showcases a mixed financial performance. The company demonstrates notable strength in solvency and profitability. However, liquidity, efficiency, and coverage ratios reveal potential areas of concern. While the company has experienced a decline in revenue and EPS growth, its operating profit and asset growth show promise. The company's ability to manage its debts is a notable strength, but its ability to meet its short-term obligations needs improvements. Overall, the company's financial health presents a complex picture, requiring further scrutiny to leverage its strengths and address its weaknesses.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-1.08
Industry Median
19.08
Small Cap Median
13.89
P/E RATIO
-1.06
P/B RATIO
0.46
Industry Median
1.32
Small Cap Median
1.22
P/S RATIO
0.20
Industry Median
1.07
Small Cap Median
0.97
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-3.75
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹29.86 as on Sep 1, 2026.
Growth Score : 4.00The company's growth performance is mixed, showing strength in operating profit and asset growth. However, it has experienced declines in revenue, EPS, and net income growth. While operating profitability and asset expansion are positive signs, the negative trends in revenue and earnings raise concerns about the company's overall growth trajectory. Addressing these factors will be crucial for sustainable long-term growth.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue Growth Rate | -13.82 | -27.04 |
| Operating Profit Growth Rate | 111.76 | -141.67 |
| Earnings Per Share (EPS) Growth | 174.17 | -760 |
| Asset Growth Rate | 9.58 | -13.93 |
| Net Income Growth Rate | 177.78 | -728.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -7.77 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 42.75 | Neutral | 4.00 | 0.20 | N/A |
| 3 | JFL Life Sciences Ltd | 6.07 | 10.88 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.89 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.06 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Sunrest Lifescience Ltd | 4.17 | 7.60 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Mangalam Drugs and Organics Ltd. is an Indian pharmaceutical company primarily engaged in manufacturing Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals. It serves diverse therapeutic areas including antimalarial, anti-inflammatory, and ophthalmic segments, catering to both domestic and international markets. The company focuses on quality and cost-effective production in its regulated facilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Mangalam Drugs and Organics Ltd's P/E ratio (TTM) is -1.08, compared to the industry median of 19.08 and large cap median of 13.89.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Mangalam Drugs and Organics Ltd's P/B ratio is 0.46, compared to the industry median of 1.32 and large cap median of 1.22.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Mangalam Drugs and Organics Ltd's P/S ratio is 0.20, compared to the industry median of 1.07 and large cap median of 0.97.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Mangalam Drugs and Organics Ltd's PEG ratio is 0.85.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Mangalam Drugs and Organics Ltd's EV/EBITDA ratio is -3.75.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Mangalam Drugs and Organics Ltd's ROE is -42.72%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Mangalam Drugs and Organics Ltd's ROA is -4.76%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Mangalam Drugs and Organics Ltd's ROCE is -14%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Mangalam Drugs and Organics Ltd's operating margin is -6.47%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Mangalam Drugs and Organics Ltd's net margin is -18.97%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Mangalam Drugs and Organics Ltd's current ratio is 0.78.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Mangalam Drugs and Organics Ltd's debt-to-equity ratio is 0.10.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Mangalam Drugs and Organics Ltd's interest coverage ratio is -2.06.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Mangalam Drugs and Organics Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Mangalam Drugs and Organics Ltd's EPS is -760.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹29.86. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1993
Headquarters: Mumbai, Maharashtra
Core Offerings: Active Pharmaceutical Ingredients (APIs), Drug Intermediates, Specialty Chemicals
Stock Listing: NSE (MANGALAM), BSE (532637)
Promoter: Jayesh P. Bangur / Bangur Group
Incorporated in 1993, Mangalam Drugs and Organics Ltd commenced commercial production in 1995. Over the years, the company expanded its manufacturing capabilities, focusing on Active Pharmaceutical Ingredients (APIs) and drug intermediates. It has consistently grown its product portfolio and market presence, serving both domestic and international pharmaceutical industries, with an ongoing focus on R&D and diversification.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients & Intermediates | Approx. 100% | Consolidated |
Active Pharmaceutical Ingredients (APIs) & Intermediates: Manufactures a wide range of APIs for various therapeutic categories including antimalarial, anti-inflammatory, anti-fungal, and ophthalmic drugs. Also produces key intermediates used in drug synthesis.
Specialty Chemicals: Engages in the production of fine chemicals that serve as precursors for pharmaceuticals and other allied industries, leveraging its chemical synthesis capabilities.
Research and Development: Operates a dedicated R&D facility focused on process optimization, new product development, and improvement of existing products to meet evolving market demands and regulatory standards.
Mr. Jayesh P. Bangur (Chairman & Managing Director): A seasoned leader with extensive experience in the chemical and pharmaceutical industry, guiding the company's strategic growth and operational excellence.
No major subsidiaries reported.
Stock split (face value from ₹10 to ₹5) in 2021. No other major recent corporate actions on record.
The Mangalam Drugs and Organics Ltd share price today is ₹29.86 on NSE (MANGALAM), as of 26 Sept 2026.
As of 26 Sept 2026, Mangalam Drugs and Organics Ltd share price is ₹29.86, with previous close ₹29.86. Today's range is ₹29.86 to ₹29.86. The 52-week range is ₹22.80 to ₹54.40.
As of today, Mangalam Drugs and Organics Ltd's market cap is ₹47.18 crore (Small Cap).
Mangalam Drugs and Organics Ltd's current P/E ratio is -1.08, compared to the CEMENT AND CONSTRUCTION sector average of 33.50.
Mangalam Drugs and Organics Ltd's current P/B ratio is 0.46.
Mangalam Drugs and Organics Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 21-Sep-2023.
Mangalam Drugs and Organics Ltd's EPS (TTM) is ₹-760.
Mangalam Drugs and Organics Ltd. is an Indian pharmaceutical company primarily engaged in manufacturing Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals. It serves diverse therapeutic areas including antimalarial, anti-inflammatory, and ophthalmic segments, catering to both domestic and international markets. The company focuses on quality and cost-effective production in its regulated facilities.
Mangalam Drugs and Organics Ltd is promoted by Jayesh P. Bangur / Bangur Group, holding 35.65% as of 26 Sept 2026.
Mangalam Drugs and Organics Ltd is listed on NSE (MANGALAM) and BSE (532637). Its next quarterly results are expected on August 2024 (Q1 FY25).
Cash Earnings Per Share (Cash EPS)
Receivable Days
